AdenoVerse Immunotherapy / Cytokine Therapy
Immuno-oncology, Autoimmune Disorders, Infectious Diseases
Not SpecifiedResearch & Development
Key Facts
Indication
Immuno-oncology, Autoimmune Disorders, Infectious Diseases
Phase
Not Specified
Status
Research & Development
Company
About Precigen
Precigen is a biopharmaceutical company specializing in innovative precision medicines for diseases with high unmet need, particularly in immuno-oncology, autoimmune disorders, and infectious diseases. The company has achieved a significant milestone with the FDA approval of PAPZIMEOS (zopapogene imadenovec-drba) for recurrent respiratory papillomatosis. Its strategic direction is built on two core, proprietary technology platforms: AdenoVerse for adenovector-based gene therapies and UltraCAR-T for rapidly manufactured, multi-gene CAR-T cell therapies, aiming to increase patient access and improve outcomes.
View full company profile